One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Access
PDF Availablehttps://doi.org/10.1136/ijgc-2021-igcs.177
Copy DOI
Export
Save
Share
Cite Publication Date: Nov 1, 2021 |
Affiliation: Confluent Private Hospital, Women's Hospital, School of Medicine, Zhejiang University, Ankara University, Fondazione IRCCS Istituto Nazionale dei Tumori, MSD (United States), The US Oncology Network, Copenhagen University Hospital, Rigshospitalet, Broward Health, National and Kapodistrian University of Athens, KU Leuven, University Hospitals Bristol NHS Foundation Trust, Institut Català d'Oncologia, University of Girona, Northwestern University, General University Hospital in Prague, Charles University, Saitama Medical University, Saitama Prefecture
ObjectivesPembrolizumab, an anti–PD-1 antibody, has demonstrated activity as monotherapy and in combination with lenvatinib in patients with previously treated mismatch repair (MMR) deficient and MMR proficient endometrial cancer (EC). ENGOT-en11/GOG-3053/KEYNOTE-B21...
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
